Comparative study between botulinum toxin and topical steroid in treatment of psoriasis vulgaris.

Arch Dermatol Res

Department of Dermatology, Faculty of Medicine, Fayoum University, Fayoum, Egypt.

Published: March 2025

Psoriasis is an immune-mediated systemic and chronic disease that can affect males and females equally. Treatments of psoriasis may and may not be effective and is based on the patients' case and severity. There is currently no cure but treatments generally can help to control the symptoms. This work aims to compare the safety and efficacy of botulinum toxin as an intralesional injection versus topical steroid in treatment of plaque psoratic patients by evaluating the PASI score as well as the clinical improvement of the cases. Twenty patients with psoriasis vulgaris were included in the study where body was splitted into two bilaterally symmetrical psoriatic plaques and treated differently one side with single intradermal injecton of botulinum toxin and the other side with topical steroid. Both treatments showed significant decrease in PASI score in two and four weeks of treatment and follow-up. There was no significant difference between the two methods; however there were small changes in the results of the score and on skin generally. Improvement of psoriasis vulgaris lesions with botulinum toxin as single application with a high safety profile proposes a good target in psoriasis vulgaris treatment; however, more investigations showed be considered.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00403-025-03986-6DOI Listing

Publication Analysis

Top Keywords

botulinum toxin
16
psoriasis vulgaris
16
topical steroid
12
steroid treatment
8
pasi score
8
psoriasis
6
comparative study
4
botulinum
4
study botulinum
4
toxin
4

Similar Publications

The Role of RAC2 and PTTG1 in Cancer Biology.

Cells

February 2025

Department of Molecular and Cellular Biology, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211a, 50-556 Wroclaw, Poland.

Several molecular pathways are likely involved in the regulation of cancer stem cells (CSCs) via Ras-associated C3 botulinum toxin substrate 2, RAC2, and pituitary tumor-transforming gene 1 product, PTTG1, given their roles in cellular signaling, survival, proliferation, and metastasis. RAC2 is a member of the Rho GTPase family and plays a crucial role in actin cytoskeleton dynamics, reactive oxygen species production, and cell migration, contributing to epithelial-mesenchymal transition (EMT), immune evasion, and therapy resistance. PTTG1, also known as human securin, regulates key processes such as cell cycle progression, apoptosis suppression, and EMT, promoting metastasis and enhancing cancer cell survival.

View Article and Find Full Text PDF

Botulinum neurotoxin (BoNT) is a highly lethal toxin produced by the anaerobic bacterium Clostridium botulinum, which leads to nerve paralysis following poisoning. At present, there is no specific drug officially approved. Antibodies, particularly single-domain antibodies, represent safe and effective candidates for specific drugs against BoNT.

View Article and Find Full Text PDF

A Review on the Expanding Role of Dentists in Facial Esthetics.

J Pharm Bioallied Sci

December 2024

Department of Clinical Dental Sciences, Ajman University, Ajman, United Arab Emirates.

Dentists' role in facial esthetics is growing, with advancements in cosmetic procedures, such as Botox and dermal fillers. Understanding the range of practitioners and their professional backgrounds is crucial for addressing risks. Data collection and analysis was done to retrieve scholarly papers using databases, such as PubMed and advanced Google search, and analyze.

View Article and Find Full Text PDF

Medication and Therapy Profiles for Pain and Symptom Management Among Adults With Cerebral Palsy.

Mayo Clin Proc Innov Qual Outcomes

April 2025

Department of Physical Medicine and Rehabilitation, Michigan Medicine, University of Michigan, Ann Arbor, MI.

Objective: To examine the most common patterns of pain and symptom management strategies among adults living with cerebral palsy (CP), and to determine if there are differences by pain phenotype or co-occurring neurodevelopmental disorders.

Patients And Methods: Federally insured beneficiaries were included if they had an ICD-9-CM/ICD-10-CM diagnosis code for CP (N=41,595). The study took place from January 10, 2024, to December 15, 2024.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!